Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
J Cyst Fibros ; 21(3): 422-433, 2022 05.
Artigo em Inglês | MEDLINE | ID: mdl-34764021

RESUMO

BACKGROUND: Previous studies suggest that PAP-based CF protocols are suitable for newborn screening (NBS) for cystic fibrosis (CF) when newborns designated as CFSPID should not be detected. However, there are still discussions about the performance of IRT/PAP algorithms. We present the final results of a pilot study evaluating a IRT/PAP protocol with an IRT-dependent safety net (SN) conducted from 2008 to 2016 in southwestern Germany on nearly 500,000 newborns. METHODS: To achieve reliable data, all newborns were screened using both the PAP-based and a DNA-based CFNBS algorithm. PAP quantification and genetic analysis of the four most common CFTR mutations in Germany were performed in all newborns with IRT≥99.0 percentile. NBS was rated positive if either PAP was ≥1.6 µg/l and/or at least one CFTR mutation was detected. In addition, an IRT-dependent SN resulted in positive rating for both protocols if IRT was ≥99.9 percentile. To evaluate the IRT/PAP protocol, its performance was compared to that of the IRT/DNA protocol. RESULTS: The IRT/PAP protocol with IRT-based SN used in the study achieved a sensitivity of 94%, if false-negative detected neonates with meconium ileus and those designated as CFSPID were excluded from analysis. CF/CFSPID ratio was 92. However, PPV of the IRT/PAP+SN protocol was with 10.3% very low. CONCLUSIONS: PAP-based CFNBS protocols can be used, if less detection of CFSPID is desired. The IRT/PAP protocol with IRT-dependent SN evaluated here achieved adequate sensitivity but should probably be used in combination with a third-tier test to also achieve an acceptable PPV.


Assuntos
Fibrose Cística , Triagem Neonatal , Fibrose Cística/diagnóstico , Fibrose Cística/genética , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Alemanha , Humanos , Recém-Nascido , Triagem Neonatal/métodos , Proteínas Associadas a Pancreatite/análise , Projetos Piloto , Sensibilidade e Especificidade , Tripsinogênio/análise
2.
Commun Biol ; 4(1): 688, 2021 06 07.
Artigo em Inglês | MEDLINE | ID: mdl-34099862

RESUMO

Persistent acinar to ductal metaplasia (ADM) is a recently recognized precursor of pancreatic ductal adenocarcinoma (PDAC). Here we show that the ADM area of human pancreas tissue adjacent to PDAC expresses significantly higher levels of regenerating protein 3A (REG3A). Exogenous REG3A and its mouse homolog REG3B induce ADM in the 3D culture of primary human and murine acinar cells, respectively. Both Reg3b transgenic mice and REG3B-treated mice with caerulein-induced pancreatitis develop and sustain ADM. Two out of five Reg3b transgenic mice with caerulein-induced pancreatitis show progression from ADM to pancreatic intraepithelial neoplasia (PanIN). Both in vitro and in vivo ADM models demonstrate activation of the RAS-RAF-MEK-ERK signaling pathway. Exostosin-like glycosyltransferase 3 (EXTL3) functions as the receptor for REG3B and mediates the activation of downstream signaling proteins. Our data indicates that REG3A/REG3B promotes persistent ADM through binding to EXTL3 and activating the RAS-RAF-MEK-ERK signaling pathway. Targeting REG3A/REG3B, its receptor EXTL3, or other downstream molecules could interrupt the ADM process and prevent early PDAC carcinogenesis.


Assuntos
Carcinoma Ductal Pancreático/metabolismo , N-Acetilglucosaminiltransferases/metabolismo , Neoplasias Pancreáticas/metabolismo , Proteínas Associadas a Pancreatite/metabolismo , Animais , Carcinoma Ductal Pancreático/patologia , Linhagem Celular Tumoral , Humanos , Sistema de Sinalização das MAP Quinases , Masculino , Metaplasia/metabolismo , Metaplasia/patologia , Camundongos Endogâmicos C57BL , N-Acetilglucosaminiltransferases/análise , Ductos Pancreáticos/metabolismo , Ductos Pancreáticos/patologia , Neoplasias Pancreáticas/patologia , Proteínas Associadas a Pancreatite/análise , Transdução de Sinais , Células Tumorais Cultivadas , Quinases raf/metabolismo , Proteínas ras/metabolismo , Neoplasias Pancreáticas
3.
Biomed Pharmacother ; 130: 110614, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32935661

RESUMO

Cancer is a critical global health-care problem with limited therapeutic options. Since cancers are life-threatening illnesses, the identification of a promising oncotarget and its clinical correlates are relevant. Mounting evidence has emerged indicating that REG gamma (REGγ), a member of the 11S proteasome activators, plays a pivotal role in the development of multiple human cancers. However, an elaborate summary on the association between REGγ and cancer is still lacking. In this Review, we discuss how REGγ, through its ATP- and ubiquitin-independent manners, represents a promising cancer biomarker and therapeutic oncotarget for multiple human cancers. Aberrant REGγ expression closely associated with tumorigenesis attributes to its biological functions for controlling and regulating cell cycle, proliferation, migration, invasion, angiogenesis, and metastasis of the cancer cells by degrading proteins of cytosol and nucleus in the eukaryotic cells. REGγ serves as a molecular switch to activate multifarious oncogenic signaling pathways, such as MAPK/p38, TGF-ß/Smad, and Wnt/ß-catenin. The review describes that targeting REGγ may provide new diagnostic and therapeutic applications in cancer.


Assuntos
Neoplasias/genética , Proteínas Associadas a Pancreatite/genética , Animais , Antineoplásicos/farmacologia , Antineoplásicos/uso terapêutico , Biomarcadores Tumorais , Proliferação de Células , Humanos , Neoplasias/patologia , Neovascularização Patológica/genética , Proteínas Associadas a Pancreatite/análise , Proteínas Associadas a Pancreatite/efeitos dos fármacos , Transdução de Sinais/genética
4.
N Engl J Med ; 383(4): 321-333, 2020 07 23.
Artigo em Inglês | MEDLINE | ID: mdl-32706533

RESUMO

BACKGROUND: Environmental enteric dysfunction (EED) is an enigmatic disorder of the small intestine that is postulated to play a role in childhood undernutrition, a pressing global health problem. Defining the incidence of this disorder, its pathophysiological features, and its contribution to impaired linear and ponderal growth has been hampered by the difficulty in directly sampling the small intestinal mucosa and microbial community (microbiota). METHODS: In this study, among 110 young children (mean age, 18 months) with linear growth stunting who were living in an urban slum in Dhaka, Bangladesh, and had not benefited from a nutritional intervention, we performed endoscopy in 80 children who had biopsy-confirmed EED and available plasma and duodenal samples. We quantified the levels of 4077 plasma proteins and 2619 proteins in duodenal biopsy samples obtained from these children. The levels of bacterial strains in microbiota recovered from duodenal aspirate from each child were determined with the use of culture-independent methods. In addition, we obtained 21 plasma samples and 27 fecal samples from age-matched healthy children living in the same area. Young germ-free mice that had been fed a Bangladeshi diet were colonized with bacterial strains cultured from the duodenal aspirates. RESULTS: Of the bacterial strains that were obtained from the children, the absolute levels of a shared group of 14 taxa (which are not typically classified as enteropathogens) were negatively correlated with linear growth (length-for-age z score, r = -0.49; P = 0.003) and positively correlated with duodenal proteins involved in immunoinflammatory responses. The representation of these 14 duodenal taxa in fecal microbiota was significantly different from that in samples obtained from healthy children (P<0.001 by permutational multivariate analysis of variance). Enteropathy of the small intestine developed in gnotobiotic mice that had been colonized with cultured duodenal strains obtained from children with EED. CONCLUSIONS: These results provide support for a causal relationship between growth stunting and components of the small intestinal microbiota and enteropathy and offer a rationale for developing therapies that target these microbial contributions to EED. (Funded by the Bill and Melinda Gates Foundation and others; ClinicalTrials.gov number, NCT02812615.).


Assuntos
Duodeno/microbiologia , Microbioma Gastrointestinal , Transtornos do Crescimento/microbiologia , Transtornos da Nutrição do Lactente/complicações , Animais , Bactérias/isolamento & purificação , Bangladesh , Duodenoscopia , Duodeno/patologia , Doença Ambiental/complicações , Fezes/microbiologia , Feminino , Vida Livre de Germes , Crescimento , Transtornos do Crescimento/etiologia , Humanos , Lactente , Doenças Inflamatórias Intestinais/complicações , Fator de Crescimento Insulin-Like I/análise , Enteropatias/complicações , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Análise Multivariada , Proteínas Associadas a Pancreatite/análise , Proteoma/análise
5.
J Cyst Fibros ; 15(6): 752-758, 2016 11.
Artigo em Inglês | MEDLINE | ID: mdl-27461140

RESUMO

BACKGROUND: In cystic fibrosis newborn screening (CFNBS), immunoreactive trypsinogen (IRT) and pancreatitis-associated protein (PAP) can be used as screening parameters. We evaluated the IRT×PAP product as second-tier parameter in CFNBS in newborns with elevated IRT. METHODS: Data on 410,111 screened newborns including 78 patients with classical cystic fibrosis (CF) from two European centers were retrospectively analyzed by discrimination analysis to identify a screening protocol with optimal cutoffs. We also studied differences in PAP measurement methods and the association of IRT and PAP with age. RESULTS: PAP values differed systematically between fluorometric and photometric assays. The IRT×PAP product showed better discrimination for classical CF than PAP only as second-tier screening parameter (p<0.001). In CF patients, IRT decreased while PAP values remained high over years. In newborns without CF, IRT decreased after birth over weeks while PAP increased within days. CONCLUSIONS: The IRT×PAP product performs well as second-tier cutoff parameter for CFNBS. Screening quality parameters depend on the analytic method and on age at blood collection.


Assuntos
Fibrose Cística , Triagem Neonatal/métodos , Proteínas Associadas a Pancreatite/análise , Tripsinogênio , Técnicas de Química Analítica , Fibrose Cística/sangue , Fibrose Cística/diagnóstico , Feminino , Humanos , Recém-Nascido , Masculino , Estudos Retrospectivos , Sensibilidade e Especificidade , Tripsinogênio/análise , Tripsinogênio/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...